Omega Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	68.78	70.96	186.82	23.29	2.62
Short-Term Investments	4.99	54.06	38.85	0	0
Cash & Cash Equivalents	73.77	125.02	225.67	23.29	2.62
Cash Growth	-40.99%	-44.60%	868.86%	790.71%	-
Receivables	6.13	0.62	0.26	0	0
Other Current Assets	9.98	11.95	3.36	0.71	0.04
Total Current Assets	89.88	137.59	229.29	24	2.65
Property, Plant & Equipment	114.05	7.86	3.61	3.48	2.83
Other Long-Term Assets	0.44	0.55	0.44	0.6	0.63
Total Long-Term Assets	114.48	8.41	4.05	4.08	3.47
Total Assets	204.37	146	233.33	28.08	6.12
Accounts Payable	1.62	3.11	2.11	1.06	0.92
Current Debt	15.3	4.86	0	3	0
Other Current Liabilities	9.89	14	9.87	3.64	1.31
Total Current Liabilities	26.81	21.96	11.98	7.7	2.23
Long-Term Debt	113.13	17.72	19.87	8.73	11.89
Other Long-Term Liabilities	6.42	0.34	0.85	1.06	1.21
Total Long-Term Liabilities	119.54	18.06	20.72	9.79	13.1
Total Liabilities	146.35	40.03	32.71	17.49	15.33
Total Debt	128.43	22.58	19.87	11.73	11.89
Debt Growth	468.77%	13.64%	69.36%	-1.35%	-
Retained Earnings	-334.63	-237.21	-134.51	-66.23	-36.78
Comprehensive Income	-0.01	-0.48	-0.06	0	0
Shareholders' Equity	58.02	105.97	200.63	-64.63	-35.92
Net Cash / Debt	-54.66	102.44	205.8	11.56	-9.28
Net Cash / Debt Growth	-	-50.22%	1680.27%	-	-
Net Cash Per Share	-1.01	2.14	9.19	2.96	-0.74
Working Capital	63.08	115.63	217.3	16.3	0.43
Book Value Per Share	1.07	2.21	8.96	-16.55	-2.87

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).